original articlesbreast cancerNeoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)†
breast cancer
Under an Elsevier user license
open archive
Keywords
triple-negative breast cancer
bevacizumab
neoadjuvant chemotherapy
pathological response rate
Cited by (0)
- †
The study was previously presented as an oral presentation at the 33rd Annual Meeting of the American Society of Clinical Oncology; 3–5 June 2011; Chicago, IL, USA.
Copyright © 2013 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.